Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GAPDH | P04406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10101489 | 1.00 | POLRMT (0.36) | POLRMTMAP4K4DOT1LHIF1ASTING1 | |
| SCHEMBL4765238 | 0.90 | POLRMT (0.35) | POLRMTMAP4K4DOT1LTNIK | |
| SCHEMBL4765244 | 0.90 | POLRMT (0.35) | POLRMTMAP4K4DOT1LTNIK | |
| SCHEMBL806951 | 0.87 | POLRMT (0.40) | POLRMTDOT1LHIF1AHSD17B10GAPDH | |
| SCHEMBL19101901 | 0.87 | POLRMT (0.40) | POLRMTDOT1LHIF1AHSD17B10GAPDH | |
| SCHEMBL10101548 | 0.87 | POLRMT (0.40) | POLRMTMAP4K4DOT1LHIF1ASTING1 | |
| SCHEMBL16479516 | 0.87 | POLRMT (0.40) | POLRMTDOT1LHIF1AHSD17B10GAPDH | |
| SCHEMBL881562 | 0.85 | POLRMT (0.40) | POLRMTDOT1LHIF1AHSD17B10GAPDH | |
| SCHEMBL18481207 | 0.82 | POLRMT (0.39) | POLRMTDOT1LHIF1AHSD17B10GAPDH | |
| SCHEMBL10101479 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119607-B2 | Bicyclic nucleosides and nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-21 | — | — | US | disclosed |
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT (AU) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035836-A1 | BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, PNP, DCTD | POLRMT 54/4885MAP4K4 2613/4885DOT1L 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.